Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 92 entries
Sorted by: Best Match Show Resources per page
[Nonalcoholic fatty liver disease: What do we know and what will we have to learn?].

Terapevticheskii arkhiv

Volkova NI, Porksheyan MI.
PMID: 28393828
Ter Arkh. 2017;89(2):91-98. doi: 10.17116/terarkh201789291-98.

The article reviews relevant data on the prevalence, natural history, pathogenesis, diagnosis, and treatment of nonalcoholic fatty liver disease and critically assesses the fixed notion of this disease.

Cite
Volkova NI, Porksheyan MI. Nealkogol'naia zhirovaia bolezn' pecheni: chto my znaem i chto predstoit uznat'. [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?]. Ter Arkh. 2017;89(2):91-98doi: 10.17116/terarkh201789291-98.
Volkova, N. I., & Porksheyan, M. I. (2017). Nealkogol'naia zhirovaia bolezn' pecheni: chto my znaem i chto predstoit uznat'. [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?]. Terapevticheskii arkhiv, 89(2), 91-98. https://doi.org/10.17116/terarkh201789291-98
Volkova, N I, and Porksheyan, M I. "Nealkogol'naia zhirovaia bolezn' pecheni: chto my znaem i chto predstoit uznat'." [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?]. Terapevticheskii arkhiv vol. 89,2 (2017): 91-98. doi: https://doi.org/10.17116/terarkh201789291-98
Volkova NI, Porksheyan MI. Nealkogol'naia zhirovaia bolezn' pecheni: chto my znaem i chto predstoit uznat'. [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?]. Ter Arkh. 2017;89(2):91-98. doi: 10.17116/terarkh201789291-98. Russian. PMID: 28393828.
Copy Download .nbib Format: NLM
Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China.

Medicine

Lin S, Xian Y, Liu Y, Cai W, Song J, Zhang X.
PMID: 29489647
Medicine (Baltimore). 2018 Mar;97(9):e0021. doi: 10.1097/MD.0000000000010021.

This study is to investigate the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and to analyze the effect of comprehensive community intervention on NAFLD in community residents in Urumqi, China.Cluster sampling method with street community as...

Cite
Lin S, Xian Y, Liu Y, et al. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China. Medicine (Baltimore). 2018;97(9):e0021doi: 10.1097/MD.0000000000010021.
Lin, S., Xian, Y., Liu, Y., Cai, W., Song, J., & Zhang, X. (2018). Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China. Medicine, 97(9), e0021. https://doi.org/10.1097/MD.0000000000010021
Lin, Sulan, et al. "Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China." Medicine vol. 97,9 (2018): e0021. doi: https://doi.org/10.1097/MD.0000000000010021
Lin S, Xian Y, Liu Y, Cai W, Song J, Zhang X. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China. Medicine (Baltimore). 2018 Mar;97(9):e0021. doi: 10.1097/MD.0000000000010021. PMID: 29489647; PMCID: PMC5851716.
Copy Download .nbib Format: NLM
Non alcoholic fatty liver: epidemiology and natural history.

Reviews on recent clinical trials

Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M.
PMID: 25514916
Rev Recent Clin Trials. 2014;9(3):126-33. doi: 10.2174/1574887109666141216111143.

Non Alcoholic Fatty Liver Disease (NAFLD), defined as the presence of a significant amount of lipid accumulation in the liver (at least in 5% of hepatocytes), represents a challenging issue for the Hepatologists. NAFLD is not represented by a...

Cite
Masarone M, Federico A, Abenavoli L, et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9(3):126-33doi: 10.2174/1574887109666141216111143.
Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., & Persico, M. (2014). Non alcoholic fatty liver: epidemiology and natural history. Reviews on recent clinical trials, 9(3), 126-33. https://doi.org/10.2174/1574887109666141216111143
Masarone, Mario, et al. "Non alcoholic fatty liver: epidemiology and natural history." Reviews on recent clinical trials vol. 9,3 (2014): 126-33. doi: https://doi.org/10.2174/1574887109666141216111143
Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9(3):126-33. doi: 10.2174/1574887109666141216111143. PMID: 25514916.
Copy Download .nbib Format: NLM
Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.

Alimentary pharmacology & therapeutics

Sinha R, Lockman KA.
PMID: 26638929
Aliment Pharmacol Ther. 2016 Jan;43(1):163. doi: 10.1111/apt.13421.

No abstract available.

Cite
Sinha R, Lockman KA. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease. Aliment Pharmacol Ther. 2016;43(1):163doi: 10.1111/apt.13421.
Sinha, R., & Lockman, K. A. (2016). Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease. Alimentary pharmacology & therapeutics, 43(1), 163. https://doi.org/10.1111/apt.13421
Sinha, R, and Lockman, K A. "Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease." Alimentary pharmacology & therapeutics vol. 43,1 (2016): 163. doi: https://doi.org/10.1111/apt.13421
Sinha R, Lockman KA. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease. Aliment Pharmacol Ther. 2016 Jan;43(1):163. doi: 10.1111/apt.13421. PMID: 26638929.
Copy Download .nbib Format: NLM
[Progress in the Management of NAFLD/NASH].

Rinsho byori. The Japanese journal of clinical pathology

Aizawa Y.
PMID: 30695468
Rinsho Byori. 2016 Jul;64(7):797-805.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. The con- cept of NAFLD ranges from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. The majority of NAFLD has been recognized as a...

Cite
Aizawa Y. [Progress in the Management of NAFLD/NASH]. Rinsho Byori. 2016;64(7):797-805
Aizawa, Y. (2016). [Progress in the Management of NAFLD/NASH]. Rinsho byori. The Japanese journal of clinical pathology, 64(7), 797-805.
Aizawa, Yoshio. "[Progress in the Management of NAFLD/NASH]." Rinsho byori. The Japanese journal of clinical pathology vol. 64,7 (2016): 797-805.
Aizawa Y. [Progress in the Management of NAFLD/NASH]. Rinsho Byori. 2016 Jul;64(7):797-805. Japanese. PMID: 30695468.
Copy Download .nbib Format: NLM
NASH Syndrome: The Coming Epidemic.

Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates

Dominguez C.
PMID: 30063688
Gastroenterol Nurs. 2018 Jul/Aug;41(4):316-320. doi: 10.1097/SGA.0000000000000334.

Nonalcoholic steatohepatitis (NASH) is a serious and rapidly growing problem affecting a population that was not previously recognized as high risk. Although treatments are limited, shedding light on those with a predisposition may allow for primary prevention, as there...

Cite
Dominguez C. NASH Syndrome: The Coming Epidemic. Gastroenterol Nurs. 2018;41(4):316-320doi: 10.1097/SGA.0000000000000334.
Dominguez, C. (2018). NASH Syndrome: The Coming Epidemic. Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates, 41(4), 316-320. https://doi.org/10.1097/SGA.0000000000000334
Dominguez, Christine. "NASH Syndrome: The Coming Epidemic." Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates vol. 41,4 (2018): 316-320. doi: https://doi.org/10.1097/SGA.0000000000000334
Dominguez C. NASH Syndrome: The Coming Epidemic. Gastroenterol Nurs. 2018 Jul/Aug;41(4):316-320. doi: 10.1097/SGA.0000000000000334. PMID: 30063688.
Copy Download .nbib Format: NLM
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.

Metabolism: clinical and experimental

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G.
PMID: 29137912
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.

BACKGROUND: Recent studies examined the prognostic impact of nonalcoholic fatty liver disease (NAFLD) on the risk of incident chronic kidney disease (CKD). However, the extent to which NAFLD may confer risk of incident CKD is uncertain. We performed a...

Cite
Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2017;79:64-76doi: 10.1016/j.metabol.2017.11.003.
Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., & Targher, G. (2018). Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism: clinical and experimental, 7964-76. https://doi.org/10.1016/j.metabol.2017.11.003
Mantovani, Alessandro, et al. "Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis." Metabolism: clinical and experimental vol. 79 (2018): 64-76. doi: https://doi.org/10.1016/j.metabol.2017.11.003
Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11. PMID: 29137912.
Copy Download .nbib Format: NLM
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health.

Hepatology (Baltimore, Md.)

Rinella M, Charlton M.
PMID: 26926530
Hepatology. 2016 Jul;64(1):19-22. doi: 10.1002/hep.28524. Epub 2016 Apr 04.

No abstract available.

Cite
Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016;64(1):19-22doi: 10.1002/hep.28524.
Rinella, M., & Charlton, M. (2016). The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology (Baltimore, Md.), 64(1), 19-22. https://doi.org/10.1002/hep.28524
Rinella, Mary, and Charlton, Michael. "The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health." Hepatology (Baltimore, Md.) vol. 64,1 (2016): 19-22. doi: https://doi.org/10.1002/hep.28524
Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 Jul;64(1):19-22. doi: 10.1002/hep.28524. Epub 2016 Apr 04. PMID: 26926530.
Copy Download .nbib Format: NLM
NAFLD/NASH and Diabetes.

Diabetes technology & therapeutics

Garg K, Brackett S, Hirsch IB, Garg SK.
PMID: 32069155
Diabetes Technol Ther. 2020 Feb;22:S174-S186. doi: 10.1089/dia.2020.2513.

No abstract available.

Cite
Garg K, Brackett S, Hirsch IB, et al. NAFLD/NASH and Diabetes. Diabetes Technol Ther. 2020;22:S174-S186doi: 10.1089/dia.2020.2513.
Garg, K., Brackett, S., Hirsch, I. B., & Garg, S. K. (2020). NAFLD/NASH and Diabetes. Diabetes technology & therapeutics, 22S174-S186. https://doi.org/10.1089/dia.2020.2513
Garg, Kavita, et al. "NAFLD/NASH and Diabetes." Diabetes technology & therapeutics vol. 22 (2020): S174-S186. doi: https://doi.org/10.1089/dia.2020.2513
Garg K, Brackett S, Hirsch IB, Garg SK. NAFLD/NASH and Diabetes. Diabetes Technol Ther. 2020 Feb;22:S174-S186. doi: 10.1089/dia.2020.2513. PMID: 32069155.
Copy Download .nbib Format: NLM
Time to step-up the fight against NAFLD.

Hepatology (Baltimore, Md.)

Zhang XJ, She ZG, Li H.
PMID: 29451316
Hepatology. 2018 Jun;67(6):2068-2071. doi: 10.1002/hep.29845. Epub 2018 Apr 19.

No abstract available.

Cite
Zhang XJ, She ZG, Li H. Time to step-up the fight against NAFLD. Hepatology. 2018;67(6):2068-2071doi: 10.1002/hep.29845.
Zhang, X. J., She, Z. G., & Li, H. (2018). Time to step-up the fight against NAFLD. Hepatology (Baltimore, Md.), 67(6), 2068-2071. https://doi.org/10.1002/hep.29845
Zhang, Xiao-Jing, et al. "Time to step-up the fight against NAFLD." Hepatology (Baltimore, Md.) vol. 67,6 (2018): 2068-2071. doi: https://doi.org/10.1002/hep.29845
Zhang XJ, She ZG, Li H. Time to step-up the fight against NAFLD. Hepatology. 2018 Jun;67(6):2068-2071. doi: 10.1002/hep.29845. Epub 2018 Apr 19. PMID: 29451316.
Copy Download .nbib Format: NLM
Past, present and future perspectives in nonalcoholic fatty liver disease.

Nature reviews. Gastroenterology & hepatology

Sanyal AJ.
PMID: 31024089
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8.

Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four decades ago. However, the condition has become the centre of attention within hepatology owing to its high prevalence and growing contribution to the burden of...

Cite
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377-386doi: 10.1038/s41575-019-0144-8.
Sanyal, A. J. (2019). Past, present and future perspectives in nonalcoholic fatty liver disease. Nature reviews. Gastroenterology & hepatology, 16(6), 377-386. https://doi.org/10.1038/s41575-019-0144-8
Sanyal, Arun J. "Past, present and future perspectives in nonalcoholic fatty liver disease." Nature reviews. Gastroenterology & hepatology vol. 16,6 (2019): 377-386. doi: https://doi.org/10.1038/s41575-019-0144-8
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8. PMID: 31024089.
Copy Download .nbib Format: NLM
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.

The European journal of health economics : HEPAC : health economics in prevention and care

Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L.
PMID: 33751289
Eur J Health Econ. 2021 Jun;22(4):505-518. doi: 10.1007/s10198-020-01256-y. Epub 2021 Mar 22.

BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) - a progressive subset of non-alcoholic fatty liver disease (NAFLD) - is a chronic liver disease that can progress to advanced fibrosis, cirrhosis, and end-stage liver disease (ESLD) if left untreated. Early-stage NASH...

Cite
Morgan A, Hartmanis S, Tsochatzis E, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021;22(4):505-518doi: 10.1007/s10198-020-01256-y.
Morgan, A., Hartmanis, S., Tsochatzis, E., Newsome, P. N., Ryder, S. D., Elliott, R., Floros, L., Hall, R., Higgins, V., Stanley, G., Cure, S., Vasudevan, S., & Pezzullo, L. (2021). Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. The European journal of health economics : HEPAC : health economics in prevention and care, 22(4), 505-518. https://doi.org/10.1007/s10198-020-01256-y
Morgan, Alice, et al. "Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018." The European journal of health economics : HEPAC : health economics in prevention and care vol. 22,4 (2021): 505-518. doi: https://doi.org/10.1007/s10198-020-01256-y
Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021 Jun;22(4):505-518. doi: 10.1007/s10198-020-01256-y. Epub 2021 Mar 22. PMID: 33751289; PMCID: PMC8166804.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 92 entries